Table 1.
Characteristics of current FDA-approved PD-1/PD-L1 checkpoint blockades.
| Drug | Brand name | Target | Company | Time approved | FDA approved indications |
|---|---|---|---|---|---|
| Pembrolizumab | Keytruda | PD-1 | Merck | 09/04/2014 12/18/2015 08/05/2016 03/15/2017 05/18/2017 05/10/2017 05/23/2017 09/22/2017 06/12/2018 06/13/2018 |
Metastatic NSCLC Unresectable or metastatic melanoma Recurrent of metastatic HNSCC Refractory cHL Advanced or metastatic urothelial carcinoma Untreated metastatic non-squamous NSCLC (combined with pemetrexed and carboplatin) Unresectable or metastatic MSI-H or dMMR solid tumors Advanced gastric cancer Recurrent or metastatic cervical cancer Refractory PMBCL |
| Nivolumab | Opdivo | PD-1 | Bristo-Myers Squibb | 12/22/2014 03/04/2015 10/09/2015 11/23/2015 05/17/2016 11/10/2016 02/02/2017 08/01/2017 09/22/2017 12/20/2017 07/10/2018 |
Unresectable or metastatic melanoma Metastatic squamous NSCLC Metastatic NSCLC Untreated advanced renal cell carcinoma Relapsed cHL Recurrent or metastatic HNSCC Advanced or metastatic urothelial carcinoma MSI-H or dMMR metastatic CRC HCC previously treated with sorafenib Resectable or metastatic melanoma Advanced RCC (Combined with ipilimumab) |
| Cemiplimab | Libtayo | PD-1 | Sanofi/Regeneron | 09/28/2018 | Metastatic CSCC |
| Atezolizumab | Tecentriq | PD-L1 | Genetech/Roche | 05/18/2016 10/18/2016 |
Advanced or metastatic urothelial carcinoma Metastatic NSCLC |
| Avelumab | Bavencio | PD-L1 | EMD Serono | 03/23/2017 05/09/2017 |
Metastatic MCC Advanced or metastatic urothelial carcinoma |
| Durvalumab | Imfinzi | PD-L1 | AstraZeneca | 05/01/2017 02/16/2018 |
Advanced or metastatic urothelial carcinoma (UK Limited) Unresectable stage III NSCLC |
FDA, US Food and Drug Administration; PD-1, programmed death protein 1; PD-L1, programmed death ligand-1; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinomas; cHL, classical Hodgkin lymphoma; MSI-H, microsatellite instability-high; dMMR, mismatch repair-deficient; PMBCL, primary mediastinal large B-cell lymphoma; CRC, colorectal cancer; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; CSCC, cutaneous squamous cell carcinoma; MCC, Merkel cell carcinoma.